Regenerating eastward

Having capitalized on the cell therapy expertise and manufacturing incentives of its European home base, Promethera Biosciences S.A. is expanding to Japan to tap the commitment to regenerative medicines among investors, pharmas and regulators.

After spending three years building its investor base in Japan and South Korea, Promethera opened a branch office last month in Tokyo, from where it hopes to find a pharma partner for HepaStem, a liver-derived mesenchymal stem cell therapy in Phase II testing. ...